Chlorhydrate de raloxifène

Tu es là: Accueil / Produits chimiques pharmaceutiques / Fat Loss Raw Powders / Chlorhydrate de raloxifène

Top Quality Pharmaceutical Powder Raloxifene Hydrochloride CAS: 82640-04-8

  • Fabricant: Dewael
  • Essai de produit: 99%+
  • Apparence:light yellow powder
  • Lieu d'origine: Chine
  • certificat: SGS,ISO9001, GMP
  • Quantité minimum d'achat: 10g
  • Détails de l'' emballage: 1 kg/sac en aluminium,25kg/drum or as your requirements
  • Heure de livraison: Dans 12 heures après réception de votre paiement
  • Modalités de paiement: Western union, MoneyGram,Bitcoin,Virement
  • livraison: EMS,DHL,Fedex,UPS,TNT et ainsi de suite.
  • Politique: Re-Politique de livraison
  • Capacité d'approvisionnement: 500-600kg/mois

Avis

Il n'y a pas encore de critiques.

Be the first to review “Raloxifene Hydrochloride

Votre adresse email ne sera pas publiée. les champs requis sont indiqués *


 

Top Quality Pharmaceutical Powder Raloxifene Hydrochloride CAS: 82640-04-8

 

Détails:

prénom:raloxifene hcl, Chlorhydrate de raloxifène
CAS No.:82640-04-8
MF:C28H28ClNO4S
Use:antineoplastic
Apparence:light yellow powder

 

spécification:

 

Nom du produit: Chlorhydrate de raloxifène
CAS: 82640-04-8
MF: C28H28ClNO4S
MW: 510.04
Catégories de produits: Active Pharmaceutical Ingredients;Raloxifene;Intracellular receptor;Aromatics;Intermédiaires & Produits chimiques fins;Médicaments;Sulfur & Selenium Compounds;Pharmaceutical intermediate
Mol File: 82640-04-8.mol
mp 250-253° C
storage temp. -20°C Freezer
solubility DMSO: 28 mg/ml, soluble
form solid
color light yellow
CAS DataBase Reference 82640-04-8(CAS DataBase Reference)
Propriétés chimiques Light-Yellow Solid
Usage A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.

 

Raloxifene Hydrochloride Description:

 

Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.

 

Raloxifene Hydrochloride Application:

 

Because of Raloxifene’s greater differences in its selectivity of Estrogen agonism and antagonism in different tissues in the body, there is ongoing investigation of its application in other diseases, including prostate cancer, acromegaly, uterine cancer, cardiovascular disease, and breast cancer.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.
Raloxifene is used to prevent and treat bone loss (l'ostéoporose) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.

 

———————————————————————————————————————————————————————————————————————————————————————-

Contacter maintenant

 

votre nom (Champs obligatoires)

votre e-mail (Champs obligatoires)

Numéro de téléphone (Champs obligatoires)

Assujettir

Votre message